Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SEC61B (Protein transport protein Sec61 subunit beta) is a single-pass integral membrane protein that forms part of the heterotrimeric Sec61 complex, the central translocon channel of the endoplasmic reticulum (ER) membrane. The Sec61 complex, comprised of alpha, beta (SEC61B), and gamma subunits, catalyzes the cotranslational and posttranslational translocation of nascent secretory and membrane proteins across or into the ER membrane[1][2]. SEC61B helps maintain the structure and stability of the Sec61 channel but is not directly involved in channel gating or substrate specificity; its deletion attenuates, but does not abolish, Sec61 function in many organisms[2]. Loss-of-function or disruption of the Sec61 complex leads to defects in protein biogenesis, ER stress, and potentially broad cellular dysfunction. There are currently no approved drugs directly targeting SEC61B, nor is it used clinically as a biomarker[2][3].
Not applicable/None established. There is no known drug mechanism directly acting on SEC61B subunit. Sec61 complex inhibitors target the functioning translocon, not specifically SEC61B.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Protein transport protein Sec61 subunit beta (SEC61B).